IMLFF - InMed Pharmaceuticals Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.4048
-0.0110 (-2.65%)
At close: 3:58PM EST
Stock chart is not supported by your current browser
Previous Close0.4158
Open0.0000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0000 - 0.0000
52 Week Range
Volume0
Avg. Volume667,133
Market Cap69.071M
Beta (3Y Monthly)0.27
PE Ratio (TTM)N/A
EPS (TTM)-0.0450
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • InMed Pharmaceuticals Reports First Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update
    PR Newswire4 days ago

    InMed Pharmaceuticals Reports First Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update

    TSX:IN OTCQX:IMLFF VANCOUVER , Nov. 12, 2018 /PRNewswire/ -  InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical ...

  • InMed Pharmaceuticals Reports First Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update
    CNW Group4 days ago

    InMed Pharmaceuticals Reports First Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update

    InMed Pharmaceuticals Reports First Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update

  • InMed Pharmaceuticals to Report First Quarter Fiscal 2019 Financial Results and Business Update on November 12, 2018
    CNW Group11 days ago

    InMed Pharmaceuticals to Report First Quarter Fiscal 2019 Financial Results and Business Update on November 12, 2018

    InMed Pharmaceuticals to Report First Quarter Fiscal 2019 Financial Results and Business Update on November 12, 2018

  • PR Newswire11 days ago

    InMed Pharmaceuticals Appoints Michael Woudenberg as Vice President, Chemistry, Manufacturing, and Controls

    OTCQX:IMLFF), a cannabinoid-based biopharmaceutical company that leverages its proprietary platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, is pleased to announce the appointment of Michael Woudenberg, P.Eng. Mr. Woudenberg joins InMed with over twenty years of leadership experience in process engineering, development and commercialization of pharmaceutical products.  Prior to joining InMed, Mr. Woudenberg served as Managing Director at Phyton Biotech, where he was responsible for the operations and manufacturing of active pharmaceutical ingredients (API) from plant cell fermentation, including contract development and manufacturing services to global pharmaceutical companies.  Prior to Phyton Biotech, Mr. Woudenberg held senior CMC-related positions at Arbutus Biopharma and Cardiome Pharmaceuticals.  Mr. Woudenberg earned his degrees in chemistry and chemical engineering from the University of Western Ontario.

  • CNW Group11 days ago

    InMed Pharmaceuticals Appoints Michael Woudenberg as Vice President, Chemistry, Manufacturing, and Controls

    OTCQX:IMLFF), a cannabinoid-based biopharmaceutical company that leverages its proprietary platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, is pleased to announce the appointment of Michael Woudenberg , P.Eng. Mr. Woudenberg joins InMed with over twenty years of leadership experience in process engineering, development and commercialization of pharmaceutical products.  Prior to joining InMed, Mr. Woudenberg served as Managing Director at Phyton Biotech, where he was responsible for the operations and manufacturing of active pharmaceutical ingredients (API) from plant cell fermentation, including contract development and manufacturing services to global pharmaceutical companies.  Prior to Phyton Biotech, Mr. Woudenberg held senior CMC-related positions at Arbutus Biopharma and Cardiome Pharmaceuticals.  Mr. Woudenberg earned his degrees in chemistry and chemical engineering from the University of Western Ontario .

  • InMed Pharmaceuticals to Present at BIO Investor Forum on October 17, 2018
    CNW Grouplast month

    InMed Pharmaceuticals to Present at BIO Investor Forum on October 17, 2018

    OTCQX: IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, will be presenting at the BIO Investor Forum on Wednesday, October 17, 2018 at 9:30 AM PT / 12:30 PM ET at the Westin St. Francis, in San Francisco , California.  The presentation will be webcast, the link to which may be found on the Company's website, or below. InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed's proprietary bioinformatics database drug/disease targeting tool, cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the Company.

  • InMed Pharmaceuticals Signs Agreement with the National Research Council of Canada for Cannabinoid Biofermentation Process Development and Scale-Up
    PR Newswirelast month

    InMed Pharmaceuticals Signs Agreement with the National Research Council of Canada for Cannabinoid Biofermentation Process Development and Scale-Up

    OTCQX:IMLFF), a cannabinoid-based biopharmaceutical company that leverages its proprietary platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, is pleased to announce entering into a research agreement with the National Research Council of Canada (NRC) in Montreal, Canada, for biofermentation development and scale-up processes for cannabinoid biosynthesis in E.coli.

  • InMed Pharmaceuticals Signs Agreement with the National Research Council of Canada for Cannabinoid Biofermentation Process Development and Scale-Up
    CNW Grouplast month

    InMed Pharmaceuticals Signs Agreement with the National Research Council of Canada for Cannabinoid Biofermentation Process Development and Scale-Up

    InMed Pharmaceuticals Signs Agreement with the National Research Council of Canada for Cannabinoid Biofermentation Process Development and Scale-Up

  • InMed Pharmaceuticals Files PCT Patent Application for the Treatment of Pain with Cannabinoids
    PR Newswire2 months ago

    InMed Pharmaceuticals Files PCT Patent Application for the Treatment of Pain with Cannabinoids

    VANCOUVER , Sept. 25, 2018 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company ...

  • InMed Pharmaceuticals Files PCT Patent Application for the Treatment of Pain with Cannabinoids
    CNW Group2 months ago

    InMed Pharmaceuticals Files PCT Patent Application for the Treatment of Pain with Cannabinoids

    InMed Pharmaceuticals Files PCT Patent Application for the Treatment of Pain with Cannabinoids

  • InMed Pharmaceuticals Reports Fourth Quarter and Full Year Fiscal 2018 Financial Results and Provides R&D and Business Update
    PR Newswire2 months ago

    InMed Pharmaceuticals Reports Fourth Quarter and Full Year Fiscal 2018 Financial Results and Provides R&D and Business Update

    VANCOUVER , Sept. 13, 2018 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company ...

  • InMed Pharmaceuticals Reports Fourth Quarter and Full Year Fiscal 2018 Financial Results and Provides R&D and Business Update
    CNW Group2 months ago

    InMed Pharmaceuticals Reports Fourth Quarter and Full Year Fiscal 2018 Financial Results and Provides R&D and Business Update

    InMed Pharmaceuticals Reports Fourth Quarter and Full Year Fiscal 2018 Financial Results and Provides R&D and Business Update

  • InMed Pharmaceuticals Announces NSERC Grant to The University of British Columbia in Support of Collaborative R&D Work
    PR Newswire2 months ago

    InMed Pharmaceuticals Announces NSERC Grant to The University of British Columbia in Support of Collaborative R&D Work

    OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform technology to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that the Company's research partner, University of British Columbia ("UBC"), has been approved to receive a grant from the Natural Sciences and Engineering Research Council of Canada ("NSERC") for their collaborative efforts with InMed in the biosynthesis of cannabinoids (the "Collaboration").

  • InMed Pharmaceuticals Announces NSERC Grant to The University of British Columbia in Support of Collaborative R&D Work
    CNW Group2 months ago

    InMed Pharmaceuticals Announces NSERC Grant to The University of British Columbia in Support of Collaborative R&D Work

    OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform technology to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that the Company's research partner, University of British Columbia ("UBC"), has been approved to receive a grant from the Natural Sciences and Engineering Research Council of Canada ("NSERC") for their collaborative efforts with InMed in the biosynthesis of cannabinoids (the "Collaboration").

  • ACCESSWIRE2 months ago

    Canadian Cannabis Stocks Flying Higher on Monday

    CORAL GABLES, FL / ACCESSWIRE / September 10, 2018 / Marijuana stocks continue to be at the head of the pack as far as new industry booms go. The industry once completely prohibited across the globe is now getting to stretch its legs as Canada readies for full legalization next month. Many pot stocks were weighed down this summer until Constellation Brands (STZ) made an additional investment into Canopy Growth (CGC) (WEED) for some $4 Billion.

  • InMed Files Patent Application for its Cannabinoid Biosynthesis Program
    PR Newswire2 months ago

    InMed Files Patent Application for its Cannabinoid Biosynthesis Program

    TSX:IN OTCQX:IMLFF VANCOUVER , Sept. 10, 2018 /PRNewswire/ -  InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical ...

  • InMed Files Patent Application for its Cannabinoid Biosynthesis Program
    CNW Group2 months ago

    InMed Files Patent Application for its Cannabinoid Biosynthesis Program

    InMed Files Patent Application for its Cannabinoid Biosynthesis Program

  • InMed Pharmaceuticals to Report Fourth Quarter, and Full Year Fiscal 2018 Financial Results and Business Update on September 13, 2018
    CNW Group2 months ago

    InMed Pharmaceuticals to Report Fourth Quarter, and Full Year Fiscal 2018 Financial Results and Business Update on September 13, 2018

    OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, will report financial results for the three and twelve months ended June 30, 2018 , which is the Company's fourth quarter of fiscal year 2018 ("4Q18"), on Thursday, September 13, 2018 .

  • InMed Pharmaceuticals to Report Fourth Quarter, and Full Year Fiscal 2018 Financial Results and Business Update on September 13, 2018
    PR Newswire2 months ago

    InMed Pharmaceuticals to Report Fourth Quarter, and Full Year Fiscal 2018 Financial Results and Business Update on September 13, 2018

    OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, will report financial results for the three and twelve months ended June 30, 2018, which is the Company's fourth quarter of fiscal year 2018 ("4Q18"), on Thursday, September 13, 2018.

  • InMed Pharmaceuticals to Present at the H.C. Wainwright 20th Annual Global Investment Conference
    PR Newswire3 months ago

    InMed Pharmaceuticals to Present at the H.C. Wainwright 20th Annual Global Investment Conference

    OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that Josh Blacher, Chief Business Officer of InMed, will be presenting at the H.C. Wainwright 20th Annual Global Investment Conference on Thursday, September 6th at 3:50 PM Eastern Time at The St. Regis New York Hotel. The presentation will be available on InMed's website. InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.

  • InMed Pharmaceuticals to Present at the H.C. Wainwright 20th Annual Global Investment Conference
    CNW Group3 months ago

    InMed Pharmaceuticals to Present at the H.C. Wainwright 20th Annual Global Investment Conference

    OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that Josh Blacher , Chief Business Officer of InMed, will be presenting at the H.C. Wainwright 20th Annual Global Investment Conference on Thursday, September 6 th at 3:50 PM Eastern Time at The St. Regis New York Hotel. The presentation will be available on InMed's website. InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.

  • CNW Group4 months ago

    InMed to Present at the Canaccord Genuity 38th Annual Growth Conference

    OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform technology to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that Eric A. Adams , President and Chief Executive Officer of InMed, will be presenting at the Canaccord Genuity 38th Annual Growth Conference on August 8 th, 2018, at 8:30 AM EST at the InterContinental Boston. The presentation will be available on InMed's website. InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.

  • PR Newswire4 months ago

    InMed to Present at the Canaccord Genuity 38th Annual Growth Conference

    OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform technology to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that Eric A. Adams, President and Chief Executive Officer of InMed, will be presenting at the Canaccord Genuity 38th Annual Growth Conference on August 8th, 2018, at 8:30 AM EST at the InterContinental Boston. The presentation will be available on InMed's website. InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.

  • OTC Markets Group Announces Quarterly Index Performance and Rebalancing
    PR Newswire4 months ago

    OTC Markets Group Announces Quarterly Index Performance and Rebalancing

    NEW YORK , July 25, 2018 /PRNewswire/ --  OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the second quarter 2018 performance ...

  • InMed Pharmaceuticals Announces the Closing of C$14.95 Million Bought Deal Financing including Full Exercise of Underwriter's Over-Allotment Option
    CNW Group5 months ago

    InMed Pharmaceuticals Announces the Closing of C$14.95 Million Bought Deal Financing including Full Exercise of Underwriter's Over-Allotment Option

    OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform technology to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that it has closed the "bought deal" financing (the "Financing") originally announced on June 12, 2018 , and that the over-allotment option of the underwriter, Eight Capital, has been exercised in full.  The total gross proceeds raised by the Company in the Financing were C$14.95 million . Due to high investor demand, the Financing was up-sized from its original amount of C$10 million to C$13 million , and the 15% over-allotment option was exercised in full, bringing the total gross proceeds of the Financing to C$14.95 million .